Lys96
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys96  -  CSDA (human)

Site Information
TkVLGTVkWFNVRNG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 466317

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 1 ) , HCT116 (intestinal) ( 3 , 4 ) , HCT8/S11 (intestinal) ( 6 , 7 ) , SNU-C2B (intestinal) ( 5 ) , SW620 (intestinal) ( 2 )

References 

1

Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520
25825284   Curated Info

2

Li Y (2006) CST Curation Set: 1828; Year: 2006; Biosample1/Treatment/Isotope: cell line, SW620/serum starved &'||' serum starved/L, Biosample2/Treatment/Isotope: cell line, SW620/serum starved/TSA/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Li Y (2006) CST Curation Set: 1810; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCT116/serum starved &'||' EGF/L, Biosample2/Treatment/Isotope: cell line, HCT116/serum starved/serum starved/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

4

Li Y (2006) CST Curation Set: 1659; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

5

Li Y (2006) CST Curation Set: 1640; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Li Y (2006) CST Curation Set: 1475; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

7

Li Y (2006) CST Curation Set: 1476; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.